Results 71 to 80 of about 3,561 (181)
Are new antiretroviral treatments increasing the risks of clinical obesity?
Journal of Virus Eradication, 2019 There is growing evidence that the use of integrase inhibitors could lead to statistically significant increases in body weight and even clinical obesity, although it is unclear whether these changes are clinically significant.
Andrew Hill, Laura Waters, Anton Pozniak
doaj +1 more source
HIV Medicine, EarlyView.Abstract Background Age‐related comorbidities occur earlier and more frequently in people with HIV (PWH) than in the general population and have emerged as a key challenge in long‐term HIV care. Unfortunately, many of these conditions remain undiagnosed, and systematic screening in clinical practice remains limited.
Anna Katrine Haslund Roed +4 more
wiley +1 more source
4-Hydroxy-5-pyrrolinone-3-carboxamide HIV-1 integrase inhibitors
, 2008 The viral enzyme integrase is essential for the replication of HIV-1 and, after the discovery of IsentressTM, represents a validated target for anti-retroviral therapy.
Pace +4 more
core +1 more source
, 2013 This chapter presents the discovery, development and evolution of integrase strand transfer inhibitors. A brief overview of the first‐generation inhibitors raltegravir and elvitegravir serves to describe their landmark advancement of the field and also outline areas for further improvement.
Brian A. Johns +2 more
openaire +4 more sources
EurosurveillanceTransmitted integrase inhibitor resistance in newly diagnosed HIV remains rare. We report two cases with baseline resistance to all currently available integrase inhibitors in the Netherlands in 2025.
Marc van der Valk
doaj +1 more source
HIV Medicine, EarlyView.Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang +15 more
wiley +1 more source
HIV Medicine, EarlyView.Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani +7 more
wiley +1 more source
Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids
Molecules, 2015 HIV integrase, encoded at the 3′-end of the HIV pol gene, is essential for HIV replication. This enzyme catalyzes the incorporation of HIV DNA into human DNA, which represents the point of “no-return” in HIV infection.
Vasu Nair, Maurice Okello
doaj +1 more source
HIV Medicine, EarlyView.Abstract Objectives Increasing rates of HIV‐1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub‐Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options.
Dominic Rauschning +16 more
wiley +1 more source
De novo design based identification of potential HIV-1 integrase inhibitors: A pharmacoinformatics study [PDF]
, 2020 In the present study, pharmacoinformatics paradigms include receptor-based de novo design, virtual screening through molecular docking and molecular dynamics (MD) simulation are implemented to identify novel and promising HIV-1 integrase inhibitors.
Chikhale, Rupesh V +6 more
core +1 more source